Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03361748 · OUTCOME

Time to Response

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
From first dose to initial response (approximately on average 1.2 months, max of 8.8 months)

What was measured

Time from first bb2121 infusion to first documentation of response of PR or better.

Analysis population: All Treated Participants with a CR or PR as per IRC

Groups in this outcome

BB2121

BB2121

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
BB2121102

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
BB21211.0Not reported0.58.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.5
        upper Limit
        8.8
        value
        1.0
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    units
    Participants
description
Time from first bb2121 infusion to first documentation of response of PR or better.
dispersion Type
Full Range
groups
  1. description
    BB2121
    id
    OG000
    title
    BB2121
param Type
MEDIAN
population Description
All Treated Participants with a CR or PR as per IRC
reporting Status
POSTED
time Frame
From first dose to initial response (approximately on average 1.2 months, max of 8.8 months)
title
Time to Response
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice